Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD

Robert F Sidonio, Jr., Angela C Weyand, Tammuella Chrisentery-Singleton, Martin Chandler, Carol Fedor, Priscilla Driscoll-Shempp, Michelle Kirby, Jorge Caicedo

Blood (2024) 144 (Supplement 1): 2594.

https://doi.org/10.1182/blood-2024-200261

Published: 2024

Journal Articles

Athn 10 - Novel Variants in Persons with Rare Coagulation Disorders across Hemophilia Treatment Centers in the United States

Diane J. Nugent, Shirley Williams, Suchitra Acharya, Christina Ashburner, Vinod V. Balasa, Nidhi Bhatt, Martin Chandler, Tammuella Chrisentery-Singleton, Nicole Crook, Hilda Ding, Carol Fedor, Ravitharan Krishnadasan, Jonathan C. Roberts, Beverly Schaefer, Ayesha Zia, Amy D. Shapiro

Blood (2024) 144 (Supplement 1): 1216.

https://doi.org/10.1182/blood-2024-201837

Published: 2024

Journal Articles

Real-World Data on Hemophilia a Patient Usage of Bay 81-8973 and Bay 94-9027 Stratified By Body Mass Index Categories in the Athndataset

Martin Chandler, Jessica Charlet, Tammuella Chrisentery-Singleton

Blood (2024) 144 (Supplement 1): 2593.

https://doi.org/10.1182/blood-2024-198690

Published: 2024

Journal Articles

Real-World Effectiveness Data on Mild and Moderate Hemophilia a Patients Using Bay 81-8973 in the Athndataset

Martin Chandler, Jessica Charlet, Tammuella Chrisentery-Singleton

Blood (2024) 144 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2024-206078

Published: 2024

Journal Articles

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD

Robert F. Sidonio, Angela C Weyand, Tammuella Chrisentery-Singleton, Martin Chandler, Haduwa Momoh, Priscilla Driscoll-Shempp, Bethany Jones, Natalia Nieto, Jorge Caicedo

Blood (2023) 142 (Supplement 1): 2613.

https://doi.org/10.1182/blood-2023-174729

Published: 2023

Journal Articles

Real-World Data on Hemophilia a Patients Transitioning from Bay 81-8973 to Bay 94-9027 and from Bay 14-2222 to Bay 81-8973 and then to Bay 94-9027 in the Athndataset

Martin Chandler, Jessica Charlet, Thomas Moulton, Michael Recht

Blood (2023) 142 (Supplement 1): 5479.

https://doi.org/10.1182/blood-2023-188995

Published: 2023

Journal Articles

Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Angela C. Weyand, Martin Chandler, Carol Fedor, Michael Recht, Robert F. Sidonio, Jr.

Blood (2022) 140 (Supplement 1): 5600–5602.

https://doi.org/10.1182/blood-2022-163302

Published: 2022

Journal Articles

Real-World Use of Octocog Alfa and Damoctocog Alfa Pegol in Women with Hemophilia a from the ATHNdataset

Martin Chandler, Jessica Charlet, Thomas Moulton, Michael Recht

Blood (2022) 140 (Supplement 1): 2751–2752.

https://doi.org/10.1182/blood-2022-166669

Published: 2022

Journal Articles

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Shannon L Carpenter, Martin Chandler, Michael F Guerrera, Lynn Malec, Matthew Manuel, Michael Recht, Ulrike Reiss, Robert F. Sidonio, Jr., Cristina Tarango, Marijke Van den Berg, Michael Wang, Courtney D. Thornburg

Blood (2022) 140 (Supplement 1): 63–64.

https://doi.org/10.1182/blood-2022-162660

Published: 2022

Journal Articles

Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset

Brian Hu, Martin Chandler, Matthew Manuel, Jorge Caicedo, Michael Denne, Bruce Ewenstein, Ali Mokdad, Shan Xing, Michael Recht

Blood (2022) 140 (Supplement 1): 2722–2723.

https://doi.org/10.1182/blood-2022-163861

Published: 2022

Journal Articles

Real-World Effectiveness of Damoctocog Alfa Pegol in the Subgroup of Adolescent Hemophilia A Patients Aged 12-18 Years in the ATHNdataset

Martin Chandler, Michael Recht, Chunla He, Thomas Moulton, Lena Charafi

Blood (2021) 138 (Supplement 1): 4241.

https://doi.org/10.1182/blood-2021-152345

Published: 2021

Journal Articles

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Angela C. Weyand, Martin Chandler, Carol Fedor, Kenneth D. Friedman, Sweta Gupta, Kristina M. Haley, Chunla He, Nikki Hirsh, Salley Pels, Jonathan C. Roberts, Tung T. Wynn, Robert F. Sidonio, Jr.

Blood (2021) 138 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2021-145631

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD

Athn 10 - Novel Variants in Persons with Rare Coagulation Disorders across Hemophilia Treatment Centers in the United States

Real-World Data on Hemophilia a Patient Usage of Bay 81-8973 and Bay 94-9027 Stratified By Body Mass Index Categories in the Athndataset

Real-World Effectiveness Data on Mild and Moderate Hemophilia a Patients Using Bay 81-8973 in the Athndataset

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD

Real-World Data on Hemophilia a Patients Transitioning from Bay 81-8973 to Bay 94-9027 and from Bay 14-2222 to Bay 81-8973 and then to Bay 94-9027 in the Athndataset

Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Real-World Use of Octocog Alfa and Damoctocog Alfa Pegol in Women with Hemophilia a from the ATHNdataset

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset

Real-World Effectiveness of Damoctocog Alfa Pegol in the Subgroup of Adolescent Hemophilia A Patients Aged 12-18 Years in the ATHNdataset

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only